Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Status:
Completed
Trial end date:
2019-05-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to
standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute